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Introduction
One of themost widely tested tissue engineering approach
for the repair and regeneration of bone defects has been the
in vitro culture of a three dimensional (3D) scaffolding
material, seeded with autologous cells, followed by
implantation inthepatient.Despite itsenormouspotential,
this regenerative strategy is generally associated with a
major pitfall. When the engineered tissue construct is
implanted, the seeded cells will have a limited capacity to
both uptake substrate molecules (oxygen, glucose, and
amino acids) and to clear byproducts of metabolism (CO2,
lactate, and urea). These limitations impair cell viability to
such an extent that it hinders the success of the engineered
tissue.[1,2] The lack of a functional microvasculature
connected to the host blood supply has been identified as
the culprit for implant failure and is currently acknowl-
edged as the major challenge in tissue engineering.[3–6]
Bone is a metabolically active tissue supplied by an
intraosseous vasculature with osteocytes distancing no
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The lack of a functional vascular supply has, to a large extent, hampered the whole range of
clinical applications of ‘successful’ laboratory-based bone tissue engineering strategies. To the
present, grafts have been dependent on post-implant vascularization, which jeopardizes graft
integration and often leads to its failure. For
this reason, the development of strategies that
could effectively induce the establishment of a
microcirculation in the engineered constructs
has become a major goal for the tissue engin-
eering research community. This review
addresses the role and importance of the devel-
opment of a vascular network in bone tissue
engineering and provides an overview of the
most up to date research efforts to develop such
a network.
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more than 100mm from an intact capillary.[2,7,8] In the
absence of a vascular supply, the transport of nutrients
occurs mainly by diffusion, a transport mechanism that is
only efficient over short distances or for tissues with low
metabolic activity (e.g., cartilage). Theoretical modeling
predicts[2] that a centimeter thick scaffoldwithout a vascular
supply can support the metabolism of 280000 cells ! cm"3
without central necrosis; in native cancelous bone,
this value is 1000-fold higher. Diffusion constrains of
engineered constructs are already an issue during in vitro
culture, in which nutrient transport is only assured to cells
on the superficial areas of the scaffold; those cells growing
at a greater depth in the construct facenutrient deprivation
and ultimately cell death.[9,10] From a clinical point of view
this is an important aspect because resection of bone
tumors or trauma originate large skeletal defects, which
require large segments of implant material to be grafted.
Mass transfer inagraft, definedas the inandoutmovement
of molecules, is a phenomenon highly impaired by the
thickness of the implant.[11] In vitro delivery of nutrients to
engineered constructs can be further improved with
dynamic culture using bioreactor systems,[12,13] however,
this will in most cases only delay further the problem of
mass transfer to the in vivo situation.
Upon graft implantation, the formation of new blood
vessels from pre-existing ones, angiogenesis, will occur
spontaneously. This vascular response is induced by
inflammation and it is part of thewound-healing generated
by the host as a response to the ischemia-reperfusion injury
formed during surgery.[3,4,14] However, capillary networks
induced by inflammatory processes are relatively transient
in nature and will regress within a few weeks.[1,15,16] In
addition to the capillary networks formed during wound
healing, neovascularization of the scaffold occurs. However,
the slow rate of infiltration of blood vessels into the scaffold
(<1mm !d"1)[4,17] makes it an insufficient process to
vascularize tissues of clinically relevant size. Another
problem associated with the lack of vascularization is the
removal of degradation products from biodegradable scaf-
folds. In the absence of a functional vasculature the capacity
of the surrounding tissue to eliminate the degradation
products derived from the implant material is very low.[18]
Consequently, there is amassive release of by-products that
accumulate locally and trigger inflammatory responses.[19]
The challenge following the development of microcircu-
lation in the engineered construct is to connect it to the
hosts’ systemic circulation, a phenomenon designated as
inosculation or anastomose.[20] Inosculation between the
host’s and construct’s vasculature is not an immediate
process and may take up to eight days; this may lead to
ischemia and a hostile environment.[21] Consequently, the
spontaneous post-implantation neovascularization from
the host is not sufficient to assure implant integration. This
creates a need for new strategies to accelerate the onset of
neovascularization.
The focus of the current review is on vascularization, in
the context of bone tissue engineering. It aims to cover the
intricate connection between vascularization and bone,
starting with the development, moving through remodel-
ing, and ending with repair. Furthermore, we will review
the most recent strategies proposed to accelerate the
establishment of a fully functional vascular network
within bone-engineered constructs.
Vascularization in Bone Tissue Engineering: Physiology, Current Strategies, Major . . .
Marina I. Santos obtained her B.Sc. in Applied
Biology from the University of Minho (Braga,
Portugal) in 2003 and a Ph.D. in Biomedical
Engineering awarded by the same university in
2009. Dr. Santos conducted her doctoral studies at
the 3B’s Research Group – Biomaterials, Bio-
degradables and Biomimetics (Department of
Polymer Engineering) under the supervision of
Prof. Rui. L. Reis and in collaboration with the
Institute of Pathology in Johannes Gutenberg
University (Mainz, Germany) under the super-
vision of Prof. C. James Kirkpatrick. Her research
has been devoted to the study of strategies to
augment vascularization in bone tissue engineer-
ing focusing on two main areas: the development
of innovative architectures and cellular appro-
aches such as co-cultures. She is currently the
author of seven papers in international refereed
journals, two book chapters, and 18 communi-
cations in conferences.
Rui L. Reis Ph.D., D.Sc., is the Director of the 3B’s
research group – Biomaterials, Biodegradables
and Biomimetics at the University of Minho in
Portugal, and the CEO of the European Institute of
Excellence on Tissue Engineering and Regenera-
tive Medicine. He is also the Head of Horizontal
R&D of the Cork Industries Holding of the
AMORIM Group and the President/Chairman
and CSO of the spin-off company Stemmatters.
He has been involved in biomaterials research
since 1990, has worked abroad for several periods,
in different Universities and companies. Prof. Rui
L. Reis is a co-author of around 360 ISI-cited
publications (around 275 full papers and a h factor
of 32) in scientific journals, around 120 book chap-
ters, several patents, six books, and several journal
special issues. He is a member of 12 international
research societies, is on the board of Tissue
Engineering & Regenerative Medicine Society
(TERMIS, World central board and EU board),
and on the board of the European Society for
Artificial Board (ESAO) and the International
Federation for Artificial Organs (IFAO). He is on
the editorial board of some of the major journals
in his field of research, and is the editor-in-chief of
the Journal of Tissue Engineering and Regenerative
Medicine.
Macromol. Biosci. 2010, 10, 12–27
! 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mbs-journal.de 13
Intraosseous Vasculature in Bone Formation,
Remodeling, and Fracture
Intramembranous and Endochondral Ossification
Aside from assuring the nutrient transport and removal of
waste products, intraosseous vasculature accomplishes
other important functions that range from bone develop-
ment, to remodelingandfracture repair.Dependingontheir
origin, bone is formedby twodistinctmodes of ossification:
by intramembranous ossification, characteristic of flat
bones such as those from skull and clavicle; and by
endochondral ossification, which is involved in the devel-
opment of bones from load bearing joints.[22,23] Despite the
differences, the two types of ossification have as common
feature: the pre-requisite of vascularization.[24–26] In
intramembranous bone formation there is an invasion of
capillaries that transport mesenchymal stem cells (MSCs),
which differentiate directly into osteoblasts and in turn
deposit bonematrix.[23] On theotherhand, in endochondral
ossification, MSCs differentiate into cartilage, which
provides a template for bone morphogenesis.[27] The
hypertrophic chondrocytes inthemineralizedcartilaginous
matrix then secret angiogenic growth factors that promote
the invasion of blood vessels, which then bring along a
number of highly specialized cells that will replace the
cartilage mold with bone and bone marrow.[23,25] Vascu-
lature also plays an important role on bone formation
through the production of growth factors that control the
recruitment, proliferation, differentiation, function, and/or
survival of various cell including bone-forming osteoblasts
and bone-resorbing osteoclasts.[26] These bioactive factors
aresecretedbyendothelialcells(ECs),thecelltypethatforms
the inner lining of blood vessels.[28–30] Therefore, angiogen-
esisnot onlyprecedesosteogenesis but it is also required for
its occurrence.[31] This is accomplished by a combination of
factors, which include adequate oxygen tension, compres-
sion forces, nutrients, and growth factors.[32]
Vascular Organization of Bone
Adult long bone is supplied by four arterial inputs, named
according to their location: nutrient artery or diaphyseal,
periosteal arteries, metaphyseal arteries, and epiphyseal
arteries. The nutrient artery is the largest vessel and
responsible for more than 50% of total blood supply to the
long bones.[33,34] As suggested by the name, periosteal
arteries supply periosteum, the membrane that covers the
exterior ofbonesand is a rich sourceof stemcells,whichhas
been tested in several regenerative strategies.[31,35] Arteries
enter the bone through the respective foramina, transverse
the cortex, reach the medullary cavity, and then branch to
supply the cortical and marrow microcirculations. In
cortical bone the vessels branch to feed the capillaries in
Havers’s and Volkmann’s canals,[36] whereas in the
marrow, arterial capillaries drain into sinusoids that are
low-pressure vascular channels surrounded by a single
layer of fenestrated endothelium.[37,38] Venous blood is
drained to the venous central sinus that runs along the
middle of the diaphysis and leaves the bone through veins
that accompany arteries.[34,36]
Bone Remodeling
Cortical and cancelous bone undergo ceaseless remodeling
starting in the 6th week of gestation and continuing
throughout adulthood.[8,36] Bone remodeling comprises
two phases, resorption of pre-existing bone tissue by the
osteoclasts, followed by de novo bone formation by the
osteoblasts.[39,40] Osteoblasts have a tight control on the
osteoclastic activity, thus balancing resorption and bone
deposition. When metabolically active, osteoblasts secret
osteoprotegerin, an inhibitor of osteoclast activity,whereas
the mature osteoblasts loose the ability to produce this
molecule and render bone vulnerable to osteoclast resorp-
tion.[41] Blood vessels direct osteoclast precursors to specific
areas of bone, i.e., to bone multicellular units (BMU).[22]
These are small compartments composed by osteoblasts,
osteoclasts, and blood vessels where remodeling takes
place.[42] In BMU resorption is initiated when the receptor
activator fornuclear factorkappaBligand(RANKL), secreted
byosteoblast, binds toRANKreceptors on theosteoclast cell
membrane.[41,43] Meanwhile, bone vessels start the second
phaseof theprocessby traffickingosteoprogenitor cells into
BMU for the deposition of new bone.[40] The invading
vasculature, therefore, serves as both a reservoir and
conduit for the recruitment of essential cell types involved
in bone resorption and deposition, regulates the functional
activities of such cells, and provides key signals necessary
for bonemorphogenesis.[32] In summary, alterations of the
microvascular supply network will ultimately affect the
tightly regulated resorption sequence to result in adecrease
in bone formation, regeneration, and repair.[22]
Fracture Repair
One of the hallmarks of bone is, upon injury, its capacity to
truly regenerate,[14] in contrast to soft tissue that heals by
forming scar tissue.[27] Fracture repair is a complex
regenerative mechanism as evidenced by the distinguish-
able processes that it involves, such as the immediate
response to injury, intramembranous bone formation,
endochondral bone formation, and bone remodeling.[44]
When bone is injured not only skeletal integrity is
compromised at the fracture site, but intraosseous vascu-
lature is clearly disrupted.[22] Firstly a hematoma is formed;
secondly, the fracture milieu becomes hypoxic because of
the disruption of oxygen supply. Hypoxia is an important
M. I. Santos, R. L. Reis
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physiological signal in bone repair because it regulates the
production of keymodulators by osteoblasts that influence
EC proliferation,[32] direct cellular differentiation,[45] and
induce ECs to secret osteogenic growth factors.[46,47] In the
hematoma phase, the first out of four overlapping phases
that characterize bone repair, a normal healing response is
triggered.[48,49] The inflammatory responseand thehypoxic
environment are associated with the release of several
growth factors and cytokines that trigger ECmigration and
the formation of new capillaries.[26,48] In fact, the recon-
struction of intraosseous circulation is one of the earliest
events during bone repair.[49,50] Meanwhile, the hypoxic
microenvironment supports the differentiation of MSCs
into chondrocytes that stabilize the fracture by cartilage
formation, known as an internal callus.[14] The periosteum
thendirectlyundergoes intramembranousbone formation,
which leads to the formation of an external callus. In the
next phase, hard callus formation, the internal callus
becomes mineralized and forms a hard callus of woven
bone. Finally, in the remodelingphase, the callus is replaced
by lamellar bone.[48]
External factors such as the biomechanical environment
also influence the bone regenerative process by affecting
angiogenesis and consequently cell differentiation.[51,52] In
a fixated fracture the vascular network is rapidly reestab-
lished and healing occurs mainly by intramembranous
ossification.[51,52] Conversely, in an unstable mechanical
environment the spreading capillaries are disrupted and
the hypoxic environment promotes the differentiation of
chondrocytes that stabilize the fracture by cartilage
formation.[14] Lack of angiogenesis has been pointed
out[51] as one of the main reasons for non-healing bone.
For instance, using a rat distraction osteogenesis model,
Fang et al.[53] have shown that the administration of an
anti-angiogenic drug prevented normal osteogenesis,
which resulted in a fibrous non-union.
Heterotypic Communication between Osteoblasts
and Endothelial Cells
Considering the intricate connectionbetweenangiogenesis
and osteogenesis, it is not surprising that communication
between osteoblasts and ECs is one of the most important
cellular interactions that orchestrate bone formation.[32,54]
The cross-talk between osteoblasts and ECs occurs at two
levels: 1) by indirect cell contact,[55,56] through the releaseof
soluble factors with paracrine and autocrine action, and 2)
by direct cell–cell contact,[57] mediated by proteins at gap
junctions. One of the most studied growth factors is
vascular endothelial growth factor (VEGF)[49,58,59], a potent
and specific angiogenic cytokine produced at the fracture
site by numerous cell types, including osteoblasts. Besides
being an EC-specific mitogen, VEGF also induces increased
vascular permeability and monocyte migration through
endothelial layers.[60] The action of VEGF is not limited to
ECs, and there are some studies reporting that osteoblasts
also respond tomembers of the VEGF family.[61–63] A recent
study[24] has shed some light on the cellular andmolecular
mechanisms responsible for controlling VEGF-dependent
osteoblast–ECs crosstalk by confirming that VEGF is
released predominantly by human osteoblasts and its
primary action is by ECs. Another angiogenic growth factor,
fibroblast growth factor (FGF), is also produced by
osteoblasts among other cell types.[64,65] FGF functions as
a paracrine factor to stimulate EC proliferation and
migration,[65] and as an autocrine factor to induce the
proliferation and differentiation of osteoblasts.[22] Further-
more, FGF-2 exerts its angiogenic effect indirectly by
modulating VEGF expression through its action over
osteoblasts.[66] Once the crosstalk between ECs and
osteoblasts is bidirectional, ECs also secret numerous
regulatorymolecules that exertmajor effects in controlling
the differentiation and activity of bone-forming cells.[32]
Bone morphogenic protein-2 (BMP-2) and endothelin-1
(ET-1) are two of the growth factors produced by ECs that
promote osteoblastic proliferation and differentiation.[67–69]
In addition, platelet-derived growth factor BB (PDGF-BB),
releasedat the fracture sitebyseveral cell types that include
ECs, has a mitogenic and chemotactic effect over osteo-
blasts.[70,71] Osteogenic growth factors produced by ECs
(BMP-2, PDGF-BB) and by osteoblasts (insulin-like growth
factor, IGF, and transforming growth factor, TGF) also have
an angiogenic effect by inducingVEGFmRNAexpression in
osteoblasts.[70,72–74] Veillette and Schroeder[75] proposed an
inhibitory role of ET-1 on VEGF synthesis in osteoblastic
cells as a feedback mechanism in the temporal and spatial
coupling of angiogenesis to bone formation and resorption.
External factors such as the hypoxic microenvironment
of fracture healing stimulate the expression of a variety of
cytokines from inflammatory cells, ECs, osteoblasts, and
fibroblasts.[76] ECs and osteoblasts respond to hypoxia by
upregulating the expression of numerous osteogenic
factors (ET-1, PDGF-BB, BMP-2, IGF-II, and TGF-b1) and of
the angiogenic growth factor VEGF.[68,76–80] The mechan-
ism underlying the response of cells to the hypoxic
microenvironment is primarily mediated through genes
whose expression contain a hypoxia-inducible factor-1
(HIF-1) binding site.[81,82] Nevertheless, it has been
reported[76,79,83] that this environment of low oxygen
tension has no effect on the expression of growth factors
such as FGF-2 and members of IGF and TGF families.
The fact thathypoxia is a driving factor for the creationof
a growth factor rich milieu inspired researchers to test its
potential benefits in engineered tissues. Several studies
have addressed oxygen tension as an important variable in
optimizing in vitro conditions for stem differentiation,[84–87]
while others[45] have hypothesized that adapting the graft
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to hypoxia prior to engraftmentmight induce angiogenesis
after implantation. It is obvious that in order to avoid the
noxious effects of low oxygen tension, culture conditions
must be well defined. On the one hand, 48h of culture do
not have a significant effect on cell death,[88] on the
other hand, long-term cultures will have a negative effect
on bone formation partly because of decreased osteoblast
proliferation.[89]
Strategies to Increment Vascularization
In order to accelerate the establishment of a functional
vascular network in bone engineered tissues several
strategies have been proposed (Figure 1). The following
sections will review the main approaches, their principles,
outcomes, and limitations.
Scaffold Architecture
The resection of tumors.[90,91] congenital deficiency,
trauma, or infection[92] are the main pathologies respon-
sible for the loss of large bone segments. Engineered bone
must assure the mechanical stability of the osseous defect,
while simultaneously stimulating the healing capacity of
the tissue. Thevastmajorityofboneregeneration strategies
have been centered on the scaffold material; however,
within the last fewyears a conceptual shift has been taking
place in the development of scaffolds for bone engineering,
froma support role for bone-forming cells, to a scaffold that
homes a vascular network. Regarding the bulk properties of
a scaffolding material, porosity has been one of the most
discussed issues[93–95]butwitha focusmainlyonosteoblast
proliferation, matrix deposition, and calcification rather
than the in penetration of vasculature. Recent work from
Narayan and Venkatraman[96] evaluated the effect of pore
size and interpore distance over ECs growth on 3D
polymeric scaffolds and found that cell growth was
enhanced by a smaller pore size (5–20mm) and lower
interpore distance. A similar behaviorwas also reported for
osteoblasts, where lower porosity stimulates osteogenesis
by suppressing cell proliferation and forcing cell aggrega-
tion in vitro.[95] However, the in vivo scenario is completely
different and a higher porosity and pore size result in
greater bone in-growth and vascularization.[95,97] This is
explained by the fact that when implanted, scaffolds with
smaller pores tend to be hypoxic, favoring chondrogenesis,
whereas in constructs with larger pores the higher oxygen
tension promotes the differentiation of MSCs into osteo-
blast lineage, favoring osteogenesis.
Hierarchical Structures
The design and architecture of the scaffold are two other
features critical for the formation of a vascular network.
One example of an innovative architecture is the nano/
micro fiber-combined scaffold (Figure 2a).[98] This scaffold
made from a blend of starch with polycaprolactone
(SPCL)[13,94,99–101] combines in the same structure micro-
andnanofibers.Microfibers obtainedbyfiber bondingwere
combinedwithnanofibersproducedbyelectrospinning ina
single structure. In thisway the scaffoldmaterial is capable
of simultaneously providing the mechanical support for
bone repair and mimicking the physical structure of the
extracellular matrix (ECM). As will be described later in
greater detail, strategies that include seeding ECs on
M. I. Santos, R. L. Reis
Figure 2. The architecture of nano/micro combined structures.
These scaffolds comprise two structures: a micro-fiber mesh to
give the mechanical support required during bone repair and a
nano-network that mimics the ECM that can be made from a)
SPCL or b) collage I. a) Scanning electron micrograph (SEM) of the
SPCL nano/micro fiber-combined scaffold. b) Confocal laser scan-
ning micrograph (CLSM) of a collagen-nano and SPCL-micro fiber-
combined scaffold stained with type I collagenwhere nano-fibers
are depicted in green fluorescence.
Figure 1. Illustration of the main five approaches to induce vas-
cularization in a bone construct.
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biomaterials and promoting their adhesion,migration, and
functionality might be a solution for the formation of
vascularized bone. Therefore, the nanonetwork that
resembles the ECM physical structure on SPCL nano/micro
fiber-combined scaffolds was designed with the aim to
promote ECmigration, and to establish a vascular network.
Underpro-angiogenic conditions in vitro, thisnanonetwork
provided the structural and organizational stability for the
migration and organization of ECs into capillary-like
structures.[102] The architecture of nano/micro-fiber-com-
bined scaffolds elicited and guided the 3D distribution of
ECswithout compromising the structural requirementsof a
scaffold for bone regeneration. Our group further tested the
combination of these structures and developed a scaffold
that comprised type I collagen nanofibers on a SPCL fiber-
mesh structure (Figure 2b).[103] Besides being one of the
main constituents of ECM, type I collagen provides
chemotactic and haptotactic signals to migrating ECs.[104]
Thus, by providing both physical and chemical cues to
enhance EC motility, the collagen-nano and SPCL-micro
fiber-combined structure might lead to an increase of
angiogenic activity. Alternatively, Yang et al.[105] used
extrusion free forming, a rapid prototyping technique to
fabricate ceramic scaffolds with three distinct structure
levels: submicrometer pores, aimed to enhance cell/surface
interactions, pores of tens of micrometers to encourage
bone ingrowth, and corridors (hundredsofmicrometers) for
vascularization. Another rather interesting concept has
been recently introducedbyBellan et al.,[106]whopromoted
the construction of a vascular network using sacrificial
sugar structures. Briefly, macro- and microfibers made of
sugar were produced by melt-spinning and included in a
polymeric matrix, such as poly(dimethylsiloxane) (PDMS).
The structure is then soaked in water and the sugar-fibers
solubilized, leaving in thepolymericmatrixmacrochannels
that can be attached to a blood supply and microchannels
with diameters close to that of capillaries.
Microfabrication of Networks with Vascular
Geometry
Another interesting concept is the inclusion of a network
with a vascular geometry in a biocompatible polymer. This
is achieved bymicrofabrication techniques that comprise a
Vascularization in Bone Tissue Engineering: Physiology, Current Strategies, Major . . .
Table 1. Microfabrication techniques used to engineer structures with vascular geometry; compiled from ref. [108,110–112,200,201]
Microfabricated Structure Substratea) Processing methodology In vitro Ref.
Network with
vascular geometry
PGS Lithography Lumens endothelialized
under flow
perfusion after 14 d
[110]
Network with
vascular geometry
PDMS Silicon microfabrication and
polymer replica molding
HMEC-1 reached
confluency after 4 d
[108]
Aligned topographical
microridges and
microgrooves
UA grafted
with PIPAAm
Photolithography and
soft lithography
ECs reach confluency
within 7 d of
culture and at
longer (2–3 weeks)
form capillary-like
tube formation
[111]
Microchannel
network
PC and PLGA Stainless steel eletroforming and
silicon electroforming
Bovine ECs dynamically
seeded reached
near-confluency after 3 d
[200]
Microchannel
network
PDMS Laser direct writing n.a. [201]
Microcapillary
structure
SU8 Two-photon polymerization n.a. [113]
a)PGS: poly(glycerol sebacate), PDMS: poly(dimethyl siloxane), UA: poly(urethane acrylate), PIPAAm: poly(N-isopropylacrylamide), SU8:
epoxy-based polymer (photosensitive), PC: Polycarbonate.
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full range of processes and tools originally developed for
applications in the microelectronics, automotive, aero-
space, and defense fields.[107] Photolithography, a process
based on semiconductor wafer technologies, has been
attracting attention. This method is a two-step process
where a mold is first produced, generally made of silica,
with an imprinted pattern. By replica-molding, the pattern
is then printed in a biocompatible polymer where the cells
will be cultured.[108] Themicrofabricated pattern can range
from aligned microgrooves to a network with vascular
geometry, which can be incorporated into a biodegradable
or non-biodegradablematerial (Table 1). In order to achieve
the best hydrodynamic performance the imprinted net-
work should be made up of multi branches with no more
than two vertical nodes in each individual branch.[109]
Fidkowski et al.[110] engineered a microvascular network
made of poly(glycerol sebacate) (PGS), a biodegradable and
functional in vivo elastomer with mechanical properties
similar toveins.To thisend, acapillarynetworkpatternwas
imprinted in PGS using microfabricated silicon wafers as
molds. By seeding the imprinted capillary networks with
ECs and perfusing them with culture medium it was then
possible to obtain a bioengineered microvascular network
in vitro. Moreover, by combining fabrication with the
principle of thermoresponsive surfaces it is possible to take
the fabrication of artificial networks to a whole new level.
By imprinting the capillary pattern in a thermoresponsive
polymer it is possible to harvest an EC tubular network that
can thenbeused in the fabricationof 3Dvascularized tissue
grafts.[111] Unfortunately, a drawback of photolithography
is its inability to create 3D architectures. Recently, a novel
computer-aided design/computer-aided manufacturing
(CAD/CAM) technologynamedtwo-photonpolymerization
(2PP) has emerged that allows the fabrication of any
computer-designed 3D structure with a structural resolu-
tion down to 100nm from a photosensitive polymer
material.[112] 2PP was applied to a photosensitive polymer
to successfully produce a microstructure with the shape of
microcapillaries.[113] The flexibility of this technology and
theability topreciselydefinea3Dconstruct geometryholds
a great potential to address issues associated with the
establishment of an intrinsic microcapillary network.
Another CAD/CAM technique used for scaffold production
is rapid prototyping.[90,114] Moroni et al.[115] developed 3D
fiber deposition, a rapid prototyping tool to create 3D
scaffolds with a hollow fiber architecture. Because of their
hollow structure these fibers can potentially provide the
physical supportwithin the3Dmatrix for the formationofa
compartmentalized vasculature.
A general remark regarding microfabrication is that
these technologies are being mainly applied to the
establishment of a complex branching vascular tree in soft
organs. A hard tissue such as bone has an increased level of
complexity, which demands microfabrication methods to
be adapted in order to simultaneously address design and
mechanical issues. For an excellent review about micro-
fabrication in the context of tissue engineering please refer
to Borenstein et al.[107]
Angiogenic Growth Factors
Because of the close association between angiogenesis and
osteogenesis, angiogenic growth factors are implicated in
neovascularization and in endochondral ossification, mak-
ing them important therapeutic agents for bone regenera-
tion.[59,116] For instance, VEGF, themain angiogenic growth
factor involved in bone healing, has an important role in
bone repair by promoting angiogenesis and by stimulating
major skeletal cell populations, chondrocytes, osteoblasts,
and osteoclasts.[117] Current approaches to therapeutic
angiogenesis focus on localized and sustained delivery of
growth factors[118,119] rather than on local and systemic
bolus injection.[120] Delivery systems permit prolonged
exposure of regenerating tissue to low and localized doses
of angiogenic factors[118,119] and are superior over bolus
injection, characterized by the lack of control over the
growth factors’ availability. A great variety of natural,[121–127]
synthetic,[128] and composite materials[129,130] have been
usedasdeliverymatrices forangiogenicgrowth factors. The
localized and sustaineddelivery ofVEGF frommacroporous
biomineralized poly(lactide-co-glycolide) (PLGA) led to
simultaneous regeneration of both vascular and bone
tissue in a cranium critical defect.[130] A particular case
where angiogenic therapy can be applied but where care
should be exerted is in defects that result from the resection
of carcinomas that failed to be eliminated with radiation
therapy.[92] In thesecasesnotonly is therea largesegmental
loss of bone but the regenerative capacity of the adjacent
tissue is also impaired because of vasculature damage by
radiation treatment.[92,131] The work of Kaigler at el.[128]
addressed this problem by delivering VEGF from PLGA
scaffolds in irradiated osseous defects. Although this
was revealed to be an effective strategy to increase
neovascularization and bone regeneration, the use of
growth factors in cancer walks the tenuous line that
separates the therapeutic and pathological effects of
angiogenic growth factors. Other drawbacks of VEGF
delivery is its inherent instability in vivo [4] and the
required high doses of recombinant protein that escalate
the therapy cost.[132]
The advances in molecular biology and drug delivery
permitted the localized delivery of the gene that codes for
the angiogenic molecule of interest. For instance, Tarkka
and collaborators[117] have used a first-generation adeno-
viral vector to deliver VEGF in a mouse femur defect and
reported that gene transfer induced angiogenesis, and
improved bone healing and bonemineral content. Another
way to promote fracture healing by means of VEGF gene
M. I. Santos, R. L. Reis
18
Macromol. Biosci. 2010, 10, 12–27
! 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim DOI: 10.1002/mabi.200900107
transfer consists in transfecting cells with the gene of
interest and thus using them as vectors. When fibroblasts
transfected with VEGF were applied to bone defects
complete bridging of new bone was observed, whereas in
the control (fibroblasts alone) the defects were fibrous and
sparsely ossified.[133]
One of the most critical and important aspects when
designing an angiogenic therapy is the dose of angiogenic
growth factor delivered.[119,134] For instance, blood vessels
formed by exposure to high doses of VEGF tend to be
malformedand leaky.[119] Inaddition, one cannotdisregard
that angiogenesis is associated to several pathologic
processes such as tumor development, atheroscleosis,
and proliferative retinopathies, so there is the risk that a
treatment with an angiogenic growth factor might
exacerbate these processes.[135] Experiments performed
byDavies et al.[134] shed somemore light on the effect of the
continued delivery of VEGF concentrations on scaffold
vascularization. They reported that the administration of
150ng a day led to a constant increase in vascularization,
even after the cessation of delivery, whereas a 10 times
higher concentration induced transient vessel growth into
the porous scaffold.
Angiogenesis can also be triggered using specific peptide
sequences derived from adhesion proteins[136] or from
moleculesof theextracellularmatrix.[137,138] Theadvantage
of these short peptide sequences over the parent protein is
the higher control over the elicited response and the
possibility to be easily grafted on a substrate.[139] Hamada
and co-authors reported that the peptide sequence Ser-Val-
Val-Tyr-Gly-Leu-Arg (SWYGLR) derived from osteopontin
exhibited potent angiogenic activity in vitro and
in vivo.[137,140] When grafts made of a carbonate–collagen
sponge that contained the SWYGLR motif were implanted
in amurine bone defect, prominent angiogenesis inside the
graft was observed just one week after the implanta-
tion.[141] Peptide sequences can also allow cell-type
selectivity. This is the particular case of the tetrapeptide
Arg-Glu-Asp-Val (REDV), a domain derived from the
adhesive protein fibronectin.[136,142] It was shown that
substrates that contained covalently immobilized REDV
peptides selectively supported the attachment and spread
of human ECs over that of other cell types.[136]
Recentlyothermoleculeswithdual actionhavealsobeen
tested. Sphingosine 1-phosphate (S1P) is a bioactive
phospholipid that affects the proliferation and migration
of ECs, smoothmuscle cells (SMCs), andosteoblast-like cells.
Because of its multiple cellular targets, S1P is an attractive
molecule forbone repair andSefcik etal.[143] haveevaluated
the sustained release of S1P-loaded microsphere-based
scaffolds in a critical-size cranial defect. Their findings have
shown that the sustained delivery of S1P significantly
stimulated new bone formation and increased vasculature
in the defect site.
Considering that angiogenesis is amultifactorial process
that involves the interplay of several factors, a way to
induce the formation of mature and stable blood vessels
includes the administration of multiple growth factors.
Kilian et al.[144,145] have tested the potential of enrichment
with a non-defined cocktail mixture of growth factors
isolated from the platelet fraction aimed to stimulate the
formation of new blood vessels in osseous defects. Using
nanoparticulate hydroxyapatite (HA), neovasculature was
formed in the defects independently of the delivery of
platelet growth factors. The low affinity of cytokines to HA
might be a reason for the lack of angiogenic effect of this
cocktail of growth factors. On the other hand, other
work[146] has tested the combined addition of both FGF-2
and VEGF to a collagen/heparin scaffold and has reported
the establishment of an early mature vasculature. Growth
factors with angiogenic properties can also be part of other
multifactorial delivery systems. For instance, the concerted
delivery of VEGF, BMP-4, and human bone marrow
mesenchymal stem cells (hBMSCs) from biodegradable
scaffolds proved to be more effective at promoting bone
formationwhen comparedwith any single or combination
of two factors.[147]
However, the real turning point in delivery systems from
a single growth factor to a dual growth factor delivery
technologycamewith the landmarkpaper fromRichardson
et al.[148] They reported a polymeric system that allows the
delivery of twoormore growth factorswith controlled dose
and rate of delivery. With the coordinated spatial and
temporal presentation of VEGF and PDGF it was possible to
obtain a rapid and mature vascular structure.[148] PDGF is
the key factor for vessel stabilization because it is
responsible for the recruitment of SMCs and peri-
cytes.[118,148] In summary, an effective and safe angiogenic
therapy is not only dependent on the right combination of
growth factors delivered but also on a temporal and dose
controlled release.
Mature and Precursor Endothelial Cells
Regardless of the approach adopted to accelerate vascular-
ization, all of the strategies will, directly or indirectly,
include ECs. Hence, in light of the critical role of ECs in the
angiogenic process, a necessary step to evaluate and
properly predict the vascularization potential of biomater-
ials is to assess the interaction of ECs with the respective
substrate.[149–151] A great number of works have examined
different aspects of ECs such as cell attachment, viability,
growth, and phenotypic/genotypic expression on different
bone substitutes: collagen,[152] silk fibroin,[153] polyether-
sulfone,[151] polycaprolactone (PCL),[154] andPLGA.[149] SPCL,
a fiber-mesh scaffold and amaterial proposed by our group
for bone regeneration,[13,94,99–101] was also revealed to be
compatible and a rather good substrate for ECs.[150]
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However, similar towhatwasobserved ina largenumberof
other polymeric substrates,[155–157] in order to sustain EC
adhesion and endothelialization the surface of the SPCL
fiber-mesh scaffolds required a pre-coating with an
adhesive protein.[150] Protein coating has several draw-
backs, namely the difficulty to control it and its stability
over time.[136] Methods such as plasma treatment,[158] UV
radiation,[159] chemical treatment,[160] and grafting with
bioactive molecules,[136] have been employed to surface-
modify polymers towards improving biocompatibility for
ECs. In the case of a SPCL fiber-mesh scaffold, to render the
surface compatible for ECswithout the need of protein pre-
coating, the material was modified with an Ar plasma. The
Ar-modified scaffolds had a performance comparable with
the fibronectin-coated substrate, i.e., the proliferation
profile of cultured ECs was similar and expression of the
endothelial markers was the same. Further investigation
revealed that the treatment by Ar plasma changed the
chemical and physical properties of the substrate and
consequently changed the adsorption pattern of the
adhesive protein vitronectin.[158]
Alternatively, ECs can be used to engineer a vascular
network, in an approach based on the principle that
transplantedECswill interactwithhostECsandvasculature,
thusestablishingavascular supplymuchfaster.Thefirst line
of evidence of a constructed vascularization as a result of EC
transplantation came from the work of Holder et al.[161]
Poly(glycolic acid) (PGA) porous matrices seeded with aortic
ECs have shown organized/unorganized ECs within the
matrix, and increasednumbers of capillaries and lymphatic-
like structures relative to the control (SMCs and skeletal
muscle cells). The feasibility of engineering a microvascular
network in vivowas later confirmed with ECs derived from
the macro- and microvasculatures.[162,163] However, Koike
et al.[6] haveshownthat inorder toobtainstable anddurable
vascular networks ECs require co-implantation with peri-
vascular cells. Thesefindingshighlight thatalthoughmature
ECshavetherequiredproliferativeandangiogenicactivity to
create vascular networks in vivo, the cooperation between
ECs and perivascular cells is fundamental for vascular
maturation.
MatureECs canbe isolated fromagreat varietyof sources
such as the umbilical cord, skin, fat tissue, and saphenous
vein. However, the low availability and proliferation
capacity are the major drawbacks of using these
cells.[164,165] There are also other problems associated with
mature ECs. Firstly, the senescent state of ECs on larger
vessels that can lead to the existence of defective signaling
pathways and thus decrease the ability to properly respond
to angiogenic growth factors.[4,30] Secondly, mature ECs
display remarkable phenotypic and genotypic heterogene-
ity in different tissues, and these differences might
generate different responses depending on the tissue from
where the cells were isolated.[29,30,166]
An alternative source of autologous ECs to support pro-
angiogenic therapies in tissue engineering are endothelial
progenitor cells (EPCs). These cells, identified through the
expression of three cellmarkers (CD133, CD34, andvascular
endothelial growth factor receptor2,VEGFR2)arepresent in
bonemarrow, fat tissue, and peripheral blood, and are able
to differentiate into mature ECs and participate in both
angiogenesis and vasculogenesis.[167,168] EPCs occur in a
low number, but when expanded in culture can undergo
more than 1 000 population doublings, in sharp contrast to
mature ECs that senesce after 30 population doublings.[169]
EPCs are a heterogeneous population composed by two
cell sub-populations: early-EPCs[170] and late-EPCs.[170,171]
As suggested by their name, early-EPCs are the first to
appear in culture generally within 4–7 d, share some
endothelial but also monocytic characteristics, and exhibit
a restricted capacity of expansion.[170] In contrast, late-EPCs
also known as blood outgrowth ECs (OECs) develop after
2–3 weeks of culture, and exhibit a cobblestone-like
morphology and long term proliferative potential.[170,171]
Regarding the differences and relevance of the different
populations of EPCs onvascularization, thework fromYoon
et al.[172] highlights the synergy between EPC populations
during neovascularization. In this work it was shown that
the injection of early EPCs (CD14þ) and OECs resulted in
superior neovascularization in vivo relative to any single-
cell-type transplantation. It was suggested that this
synergy between EPC populations might be a result of
different contributions: early EPCs may contribute to
neovascularization by secretion of cytokines and matrix
metalloproteinase-8 (MMP-8), whereas OECs participate by
providing building blocks and secreting MMP-2.
The phenotypic stability in culture that characterizes
OECs[171] has also been demonstrated in 3Dmatrices. OECs
have been used in combination with fibroin silk fiber
meshes for application in tissue engineering and the results
have shown endothelialization of fibroin silk fiber meshes,
while maintaining their endothelial characteristics and
functions.[173] Furthermore, when embedded in a wound-
healing matrix, OECs migrated from the fibroin scaffolds
and formed a microvessel-like network in vitro.
EPCs have already been successfully applied in the
treatment of fracture healing.Matsumoto et al.[174] demon-
strated that transplantation of EPCs can be a successful
strategy for the treatment of delayed fracture unions.
Briefly, EPCs were systemically transplanted and recruited
to the osseous fracture by factors present in the healing
environment. Once within the fracture site, the trans-
planted cells enhanced vasculogenesis/angiogenesis and
osteogenesis, which led to fracture healing. However, in
order to avoid large systemic doses of EPCs and potential
side effects,[175] later on the same group refined the
strategy.[176] For that, EPCs were seeded in the femoral
non-union site and mobilized by local delivery of granu-
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locyte colony stimulating factor, hence promoting fracture
union.
Similarly, as reported for mature cells, for EPCs to form
stable and long-lasting microcapillary structures, the
construct requires a perivascular component.[177,178] For
instance, it has been found that seeding EPCs in poly-
(glycolic acid)/poly(L-lactic acid) (PGA-PLLA) preserved the
endothelial phenotype but the formation of microvessels
in vitro was only observed when SMCs were added to the
culture.[169] In the same research line, the formation of
functionalmicrovascular beds in immunodeficientmice by
co-implantation of EPCs andmesenchymal progenitor cells
isolated from blood and bone marrow, respectively, were
reported.[179]
Co-Culture Systems
Bone is a complex tissue and this is well present in the
multitude of cell populations that compose it. Hence, it is
expected that theco-cultureofheterogeneouscell typeswill
recreate more closely the in vivo environment than single-
cell cultures.[154,180] As previously described, one of the
most important heterotypic cross-talks in fracture is the
one betweenECs and osteoblasts.Many researchers[181–183]
have tested this relationship and have designed strategies
to regenerate a vascularized bone construct based on the
simultaneous culture of these two cell types. Co-cultures
may be applicable to a prevascularization strategy for
biomaterials prior to implantation[183] or to a post-
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Table 2. Co-culture systems for vascularization of bone constructs; compiled from the Ref. [102,154,181–186,191,202,203]
Components of
co-culture systema)
Substrateb) In vivo Ref.
HUVEC hOBs Tutobone1 Recruitment of mural
cells and anastomose
with host vasculature
[191]
HUVEC hOBs Polyurethane scaffolds n.a. [184]
Cell line
HBMEC-60
Bone marrow
fibroblasts
PCL scaffold n.a. [154]
HDMEC hOBs or MG-63 Several 3D bone materials n.a. [183]
HDMEC hOBs SPCL fiber-mesh scaffolds n.a. [102]
HUVEC hOBs Collagen gel n.a. [202]
OECs hOBs or MG-63 Scaffold-free approach n.a. [182]
HUVEC hMSCs Scaffold-free approach Limited anastomose with
host vasculature
[181]
Kidney vascular
ECs
MSCs PLGA scaffolds Neovasculature and
bone formation
[203]
EPCs hOBs PCL-HA scaffolds Establishment of
capillary network
and osteoid formation
[185]
Adipose tissue
stromal cells
Porous HA ceramic
scaffolds
Formation of ectopic bone
tissue and blood
vessels connected to
host vasculature
[186]
a)hOBs: primary human osteoblasts, hMSCs: human mesenchymal stem cells, HUVEC: human umbilical vein endothelial cells, HDMEC:
human dermal microvascular endothelial cells, EPCs: endothelial progenitor cells. b)Tutobone1: processed bovine cancellous bone, PCL-
HA: polycaprolactone-hydroxiapatite.
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implantation vascularization strategy. The co-culture
system of ECs and osteoblasts can be used in different
ways such as in scaffold-free approaches (e.g., spher-
oids)[181,182] or in conjunction with 3D scaffolds[184,185]
(Table 2). Furthermore, fully differentiated mature[183,184]
or progenitor cells isolated from several sources[176,182] can
make-up the co-culture system.Althoughnormally ECs and
osteoblasts are isolated from different sources, from the
clinical point of view it is easier to obtain the two cell
populations from a common cell source, as has been
described for adipose tissue and bone marrow.[185,186]
It has been reported by several authors[102,183,184] that
ECs co-cultured with osteoblasts are able to establish
microcapillary-like structures in a 3D scaffold and that
these vascular structures are stable in in vitro culture for up
to 42 d (Figure 3a–c). Furthermore, the complexity of these
structures formed by ECswas confirmed by the presence of
a patent lumen and by the expression in the perivascular
region of type IV collagen, the major constituent of
endothelial basement membrane. The great advantage of
this strategy is its self-sustainability, i.e., the interaction
betweenthetwocell populations recreates thephysical and
chemical environment favorable for the formation of
vascular-like structures, thus obviating the exogenous
supply of angiogenic stimuli. Regarding the mechanisms
and factors that underlie the cross-talk communication
between ECs and osteoblasts it has been shown[102,183,187]
that osteoblasts in co-culture with ECs released higher
amounts of the pro-angiogenic factor VEGF than in
monoculture. However, in addition to soluble factors,[183]
molecules from the ECM[102,188] play an important role in
the orchestration of co-culture. In agreement with other
studies of 2D co-cultures,[55] our group has shown that co-
cultureofhumandermalmicrovascular ECs (HDMECs)with
osteoblasts on a SPCL fiber-mesh scaffold triggered collagen
type I mRNA and protein synthesis (Figure 3d).[102] Hence,
collagen type I is a key molecule and modulator in the co-
culture system in that it provides chemical and physical
cues formigration and proliferation of ECs. In addition, ECs
also influence the activity of osteoblasts and up-regulate
the expression of alkaline phosphatase (AP), an indicator of
the effect of ECs on osteogenic differentiation.[181,189]
Another major issue in co-culture is the direct cell–cell
contact. Interestingly, when conditioned medium from
osteoblasts was added to ECs or when the two cell types
were co-cultured physically separated by a filter, no
formation of a microcapillary-like structure was
observed.[183] Also in support of these findings is the report
that changes in the expression of several genes in both cell
populations were dependent on cell-to-cell contact and
were not seen in conditioned supernatants.[189,190] Con-
nexin-43 (Cx43) is pointed out as the gap junction protein
thatmediates the intracellular exchangesof regulatory ions
and small molecules between ECs and osteoblasts.[56,57]
Studies fromVillars et al.[57] have confirmed the role of this
gap junction in this heterotypic communication by
showing that its inhibition decreased the effect of human
umbilical vein endothelial cell (HUVEC) co-cultures on
hBMSC differentiation.
Long term in vitro co-culture holds the promise that in
vitro pre-vascularization might accelerate the establish-
ment of a vascular supply within the implanted scaffold;
however, it remains to be determined whether these
microcapillary-like structures pre-formed in the biomater-
ial are able to establish efficient connections with the host
microvasculature. An alternative to the in vitro establish-
ment of a microcapillary network is to co-culture ECs and
osteoblasts in the scaffolding material for a short time
(hours to few days) followed by implantation. This
approach takes advantage of the in vivo environment to
orchestrate the cellular interaction for the establishment of
a functional vasculature. In the work of Yu et al.[185] an
implanted co-culture of EPCs and bone marrow-derived
osteoblasts on porous PCL not only improved osteogenesis
but also enhanced vascularization that consequently
prevented the ischemic necrosis at the center of the graft.
In contrast,when the samescaffoldingmaterialwas seeded
with osteoblasts alone it impaired osteogenesis and was
accompanied by progressive necrosis of the graft. Steffens
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Figure 3. Co-culture system of HDMEC and primary osteoblasts on
a SPCL fiber-mesh scaffold. a,b) After 21 days of culture HDMEC
organized into microcapillary-like structures with linear and
branched forms. In order to distinguish between the two cell
populations the sample was stained for CD31 (green fluorescence,
endothelial-specific) and nuclei (blue fluorescence, both osteo-
blasts and HDMECs). c,d) After 35 d immunohistochemical stain-
ing of thin sections of the co-culture system was performed.
Sections were stained for the endothelial marker PECAM-1 (CD31)
(c) and for collagen type I (d). $ Identifies the scaffold material.
The values of the scale bars are: a) 300, b) 67, c) 20, and d) 50mm.
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et al.[191] also reported the formation of vasculature after
implanting sub-cutaneously into immunodeficient mice a
co-culture of mature ECs and osteoblasts on bovine
cancelous bone. Specially worth mentioning was the fact
that vasculaturewas stabilizedby the recruitment ofmural
cells and that the newly formed vascular networks
anastomosed with the mouse vasculature.
Microsurgery Strategies
A vascularized graft can be obtained from a hybrid
approach that combines microsurgery approaches with
bone tissue engineering concepts. Biomaterials, osteogenic
cells, and osteoinductive growth factors have been used for
the creation of vascularized bone tissues in combination
withmicrosurgery approaches such as flap fabrication and
arteriovenous loop.[192] In flap fabrication the engineered
structure relies on the extrinsic blood supply, by which
vascular ingrowth occurs from the surrounding tissues.[193]
It basically consists of a two-stage surgical procedure,
where in thefirst stage the scaffoldingmaterial loadedwith
cells and/or growth factors is implanted into a site of
rich vascularization, usually a muscle or the forearm
fascia.[20,194] Capillary ingrowth from the recipient site
vascularizes the scaffold, and in the second stage thegraft is
transferred as free bone flap to the defect and by
microvascular surgery the vascular pedicle is anastomosed
with vessels at the recipient site. Many researchers have
tried to further develop this concept.[195–197] For instance,
the clinical studies performed by Warnke et al.[90] took the
concept of combining tissue engineering with flap fabrica-
tion to a new level. They accomplished mandible recon-
struction by combining a custom-made scaffold with bone
morphogenetic protein 7 (BMP-7) and the patient’s bone
marrow. The construct was then implanted into the
lastissimus dorsi muscle for 7 weeks and later transferred
as a free bone-muscle flap to repair the mandibular defect.
The mandible replacement remarkably improved the
patient’s quality of life and retained its function over
13 months, until the death of the patient from cardiac
arrest.[91] Despite the successful outcome of this approach
one can not disregard its drawbacks such as the incon-
venience of two surgical interventions and donor-site
morbidity in sacrificing the attached muscle.[193]
Vascularization of porous matrices can also be accom-
plished by implantation of an arteriovenous loop around
the construct. The advantages over flap fabrication is that
the arteriovenous loop accomplishes vascular growthwith
minimal fibrosis,[194] the construct acquires an inherent
perfusion, and does not need to rely on favorable local
conditions.[192] Kneser et al.[192] reported the induction of
axial vascularization in a processed bovine cancelous bone
matrix by means of a microsurgically constructed arter-
iovenous loop. In addition, the induction of vascularization
in scaffolding material prior to cell injection may help to
increase the initial survival and engraftment of trans-
planted cells and may consecutively optimize bone
formation in bioartificial osteogenic bone tissues.[198] The
work of Lokmic et al.[199] took this concept further and
developed amodelwhere anarteriovenous loop is placed in
a non-collapsible space protected by a polycarbonate
chamber aimed to provide a proper vascularized environ-
ment for a successful cell transplantation. They hypothe-
sized that the optimal timepoint for exogenous cell seeding
would be in the period of intense angiogenesis, i.e., 7 to
10 days after implantation. However, there are some
drawbacks associated to arteriovenous loop; there is
the technical challenge of loop fabrication and the donor
site morbidity caused by removal of the donor’s vein
graft.[3,21]
Conclusion and Future Challenges
In the last few years we have observed a shift in the
paradigm of bone tissue engineering. The major players
havealwaysbeenosteoblastsandtheosteoconductiveand/
or inductive properties of the biomaterials, and bone
vasculature was typically relegated. Lately, this scenario
has been changing, since it became clear that the successful
clinical outcome of the implanted cell-constructs is
dependent on the establishment of a functional vascular
network. Furthermore, a large body of evidence emerged
that highlights the crucial role of intraosseous vasculature
in bone development, repair, and remodeling. The intricate
relation between angiogenesis and osteogenesis has been
unveiled and the cross-talk between osteoblasts and ECs
was identified as one of the most important cellular
interactions that orchestrates bone processes. Several
strategies for the acceleration of neovascularization either
in vivo or in vitro have been proposed and tested. As revised
in thiswork, it is possible to establish capillary networks by
several approaches: by the addition of angiogenic growth
factors that elicit an angiogenic response in vivo, by the
seeding ofmature and progenitor ECs, by the incorporation
of microcapillary-like structures into the scaffold design
that could provide the necessary physical cues for ECs, by
exploring the unique relation between ECs and osteoblasts
through co-culture systems, and by combining microsur-
gery techniques with tissue engineering concepts.
Despite the great achievement that was the establish-
ment of capillary structures on bone constructs, these
vascular structures were revealed to be unstable and prone
to regression. Hence, at the present moment, efforts are
mainly centered on stabilizing neovasculature and thus
promoting the formation of long-lasting blood vessels.
Perivascular cells such as pericytes and SMCs contribute to
the remodeling and maturation of the primitive vascular
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network and are, therefore, fundamental agents in the
construction of durable engineered vasculature. In this line
of thought, the strategy of dual growth factor delivery
encompasses the release of growth factors to promote EC
activity and the recruitment of perivascular cells in
separate phases. In addition, it is also expected that the
complexity of co-culture systems will be upgraded and tri-
cultures that encompass the triad of osteoblasts, ECs, and
mural cells will be the adopted system.
An issue equally important to the establishment of
microcirculation in the engineered construct is its anasto-
mose with host circulation. If this connection to the
recipient’s site is not accomplished, the vascularization
strategy is jeopardized. The existing technology allows the
connection to host vasculature of vessels with a minimum
diameter of 1mm. The solution passes either by the
establishment of vessels with larger caliber or by the
improvement of vascular surgery techniques.
The reconstruction of lesions that involve both vascular
and avascular tissue, such as osteochondral defects, raises a
new challenge. The regeneration of osteochondral defects
implies not only the development of biphasic systems that
meet the distinct mechanical/metabolic requirements of
bone and cartilage, but also an integrated system that
compartmentalizes and limits vascularization to the bone
phase.
The takehomemessage is thatbone is amulticomponent
system and any successful vascularization strategy of a
bone engineered-construct must be able to recreate each of
the individual elements and the intricate network of
connections between them. All bone tissue engineering
strategiesmust take that into relevant account or theywill
always be prone to failure.
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